



Special Track Session 2

Thyroid Committee

Sunday, October 20, 09:45 - 11:15

Session Title

Challenge the Expert: Therapeutic Dilemmas in Patients with Low-Intermediate Risk Thyroid Cancer

Moderators

Petra Petranovic Ovcaricek (Zagreb, Croatia)

Michael Kreissl (Magdeburg, Germany)

Expert

Alfredo Campennì (Messina, Italy): Iodine-131 therapy in lower-risk Differentiated Thyroid Cancer (DTC) patients: is it really only to facilitate the follow-up?

Challengers: Team Zurich

Alexander Maurer (Zurich, Switzerland)

Eva Deininger Czermak (Zurich, Switzerland)

Stephan Beintner (Zurich, Switzerland)

Magdalena Kulgawczuk (Zurich, Switzerland)

Tatjana Leike (Lucerne, Switzerland)

Educational Objectives

The present Special Track session intends to provide an updated overview regarding the clinical, diagnostic and, especially, therapeutic management of patients affected by low or intermediate-risk differentiated thyroid cancer (DTC) taking into account both the latest guidelines/literature data and the real life clinical scenario. In particular, the interaction between Expert and Challengers will be able to offer:

1. Pros and cons (if any) of iodine-131 therapy in low-risk DTC patients
2. Pros and cons (if any) of iodine-131 therapy in intermediate-risk DTC patients
3. An overview on the impact of local factors on decision making process
4. Suggestions for radioiodine activities and strategies for iodine-131 therapy
5. Suggestions regarding the best timing to perform nuclear medicine imaging studies
6. How to manage the first follow-up (i.e. evaluating of response to initial treatments).

Summary

This Special Track session is intended to cover whole aspects of radioiodine therapy in patients affected by low or intermediate-risk Differentiated Thyroid Cancer. In addition, the more correct use of diagnostic nuclear medicine imaging in the staging and/or follow-up of such patients will be discussed as well. Accordingly, the session has been arranged *as a challenge to the expert* offering both an updated overview on the present role and usefulness of radioiodine therapy in low or intermediate-risk DTC patients and trying to solve common issues/controversies from real life by a debate between Expert and Challengers on clinical cases.

Key Words

Low-risk Differentiated Thyroid Cancer; Intermediate-risk Differentiated Thyroid Cancer; Iodine-131 therapy; ablative purpose; adjuvant purpose; staging of Differentiated Thyroid Cancer patients; response assessment in Differentiated Thyroid Cancer patients